{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:05:03Z","timestamp":1768547103569,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Peripheral neuropathy (PN) is common in patients with multiple myeloma (MM). We hypothesized that the relationship between hypovitaminosis D and PN described in diabetes mellitus patients may also be present in MM patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To study this potential association, we assessed the incidence of hypovitaminosis D (vitamin D\u2009&lt;\u200975\u00a0nmol\/L [=\u200930\u00a0ng\/mL]) in smouldering and active MM patients in two Dutch hospitals. Furthermore, a validated questionnaire was used to distinguish different PN grades.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 120 patients included between January 2017 and August 2018, 84% had an inadequate vitamin D level (median vitamin D level 49.5\u00a0nmol\/L [IQR 34\u201365\u00a0nmol\/L]; mean age: 68\u00a0years [SD\u2009\u00b1\u20097.7]; males: 58%). PN was reported by 69% of patients (n\u2009=\u200983); however, of these 83 patients, PN was not documented in the medical records of 52%. An association was found between lower vitamin D levels and higher incidence of PN in the total population (P\u2009=\u20090.035), and in the active MM patients (P\u2009=\u20090.016).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This multi-centre cohort study showed that PN and hypovitaminosis D are common in MM patients, and addressing low vitamin D levels in the treatment of MM patients might be beneficial in reducing the risk of PN. More attention for PN is warranted, as PN is underreported by clinicians. Further research is needed to fully understand the implications of vitamin D in the development of PN in patients with MM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>Netherland Trial Register NL5835, date of registration July 28, 2016<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-021-06414-3","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T14:02:37Z","timestamp":1626530557000},"page":"271-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-9144","authenticated-orcid":false,"given":"B. E.","family":"Oortgiesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Kroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Scholtens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hoogland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dannenberg - de Keijzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Siemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. G. A.","family":"Jansman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. E.","family":"Kibbelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. J. G. M.","family":"Veeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hoogendoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. N.","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"6414_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128. https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"6414_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","volume":"69","author":"R Plasmati","year":"2007","unstructured":"Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E, Tosi P, Cangini D, Tacchetti P, Salvi F, Bartolomei I, Michelucci R, Tassinari CA (2007) Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 69:573\u2013581","journal-title":"Neurology"},{"key":"6414_CR3","unstructured":"European Medicines Agency (2010) Summary of product characteristics of bortezomib. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/velcade-epar-product-information_en.pdf"},{"key":"6414_CR4","unstructured":"European Medicines Agency (2018) Summary of product characteristics of thalidomide. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/thalidomide-celgene-epar-product-information_en.pdf"},{"key":"6414_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hon.2149","volume":"33","author":"M Morawska","year":"2015","unstructured":"Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M (2015) Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 33:113\u2013119. https:\/\/doi.org\/10.1002\/hon.2149","journal-title":"Hematol Oncol"},{"key":"6414_CR6","doi-asserted-by":"publisher","first-page":"e0123866","DOI":"10.1371\/journal.pone.0123866","volume":"10","author":"J Minarik","year":"2015","unstructured":"Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R, Czech Myeloma Group (2015) Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One 10:e0123866. https:\/\/doi.org\/10.1371\/journal.pone.0123866","journal-title":"PLoS One"},{"key":"6414_CR7","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113\u20133120","journal-title":"J Clin Oncol"},{"key":"6414_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","volume":"51","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Jakubowiak AJ (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 51:1178\u20131187. https:\/\/doi.org\/10.3109\/10428194.2010.483303","journal-title":"Leuk Lymphoma"},{"key":"6414_CR9","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00520-015-3032-y","volume":"24","author":"AJ Beijers","year":"2016","unstructured":"Beijers AJ, Vreugdenhil G, Oerlemans S, Eurelings M, Minnema MC, Eeltink CM, van de Poll-Franse LV, Mols F (2016) Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer 24:2411\u20132420. https:\/\/doi.org\/10.1007\/s00520-015-3032-y","journal-title":"Support Care Cancer"},{"key":"6414_CR10","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22921","volume":"110","author":"A Badros","year":"2007","unstructured":"Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110:1042\u20131049. https:\/\/doi.org\/10.1002\/cncr.22921","journal-title":"Cancer"},{"key":"6414_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","volume":"13","author":"V Chaudhry","year":"2008","unstructured":"Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I (2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 13:275\u2013282. https:\/\/doi.org\/10.1111\/j.1529-8027.2008.00193.x","journal-title":"J Peripher Nerv Syst"},{"key":"6414_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/ajh.23835","volume":"89","author":"P Tacchetti","year":"2014","unstructured":"Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Cavaletti G, Palumbo A, Cavo M (2014) Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hematol 89:1085\u20131091. https:\/\/doi.org\/10.1002\/ajh.23835","journal-title":"Am J Hematol"},{"key":"6414_CR13","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518\u20133525. https:\/\/doi.org\/10.1200\/JCO.2008.18.3087","journal-title":"J Clin Oncol"},{"key":"6414_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10072-016-2542-9","volume":"37","author":"C Leone","year":"2016","unstructured":"Leone C, Federico V, La Cesa S, Russo E, Di Stefano G, Finsinger P, Labriola R, Cruccu G, Petrucci MT, Truini A (2016) An observational study assessing peripheral neuropathy related to multiple myeloma. Neurol Sci 37:1141\u20131143. https:\/\/doi.org\/10.1007\/s10072-016-2542-9","journal-title":"Neurol Sci"},{"key":"6414_CR15","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1080\/10428190903111922","volume":"50","author":"SA Zivkovi\u0107","year":"2009","unstructured":"Zivkovi\u0107 SA, Lacomis D, Lentzsch S (2009) Paraproteinemic neuropathy. Leuk Lymphoma 50:1422\u20131433. https:\/\/doi.org\/10.1080\/10428190903111922","journal-title":"Leuk Lymphoma"},{"key":"6414_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/hon.2417","volume":"36","author":"E Rosenbaum","year":"2018","unstructured":"Rosenbaum E, Marks D, Raza S (2018) Diagnosis and management of neuropathies associated with plasma cell dyscrasias. Hematol Oncol 36:3\u201314. https:\/\/doi.org\/10.1002\/hon.2417","journal-title":"Hematol Oncol"},{"key":"6414_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.beha.2005.01.024","volume":"18","author":"A Dispenzieri","year":"2005","unstructured":"Dispenzieri A, Kyle RA (2005) Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18:673\u2013688","journal-title":"Best Pract Res Clin Haematol"},{"key":"6414_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/0976-500X.95506","volume":"3","author":"R Nair","year":"2012","unstructured":"Nair R, Maseeh A (2012) Vitamin D: The \u201csunshine\u201d vitamin. J Pharmacol Pharmacother 3:118\u2013126. https:\/\/doi.org\/10.4103\/0976-500X.95506","journal-title":"J Pharmacol Pharmacother"},{"key":"6414_CR19","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jcot.2019.07.004","volume":"10","author":"N Charoenngam","year":"2019","unstructured":"Charoenngam N, Shirvani A, Holick MF (2019) Vitamin D for skeletal and non-skeletal health: what we should know. J Clin Orthop Trauma 10:1082\u20131093. https:\/\/doi.org\/10.1016\/j.jcot.2019.07.004","journal-title":"J Clin Orthop Trauma"},{"key":"6414_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1210\/er.2012-1000","volume":"33","author":"CJ Rosen","year":"2012","unstructured":"Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, Murad MH, Kovacs CS (2012) The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 33:456\u2013492. https:\/\/doi.org\/10.1210\/er.2012-1000","journal-title":"Endocr Rev"},{"key":"6414_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000342771","volume":"61","author":"T Mezza","year":"2012","unstructured":"Mezza T, Muscogiuri G, Sorice GP, Prioletta A, Salomone E, Pontecorvi A, Giaccari A (2012) Vitamin D deficiency: a new risk factor for type 2 diabetes? Ann Nutr Metab 61:337\u2013348. https:\/\/doi.org\/10.1159\/000342771","journal-title":"Ann Nutr Metab"},{"key":"6414_CR22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/bloodadvances.2019001411","volume":"4","author":"SV Yellapragada","year":"2020","unstructured":"Yellapragada SV, Fillmore NR, Frolov A, Zhou Y, Dev P, Yameen H, Ifeorah C, Do NV, Brophy MT, Munshi NC (2020) Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv 4:1643\u20131646. https:\/\/doi.org\/10.1182\/bloodadvances.2019001411","journal-title":"Blood Adv"},{"key":"6414_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40618-014-0210-6","volume":"38","author":"WS Lv","year":"2015","unstructured":"Lv WS, Zhao WJ, Gong SL, Fang DD, Wang B, Fu ZJ, Yan SL, Wang YG (2015) Serum 25-hydroxyvitamin D levels and peripheral neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis. J Endocrinol Invest 38:513\u2013518. https:\/\/doi.org\/10.1007\/s40618-014-0210-6","journal-title":"J Endocrinol Invest"},{"key":"6414_CR24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s10072-015-2207-0","volume":"36","author":"A Alamdari","year":"2015","unstructured":"Alamdari A, Mozafari R, Tafakhori A, Faghihi-Kashani S, Hafezi-Nejad N, Sheikhbahaei S, Naderi N, Ebadi M, Esteghamati A (2015) An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects. Neurol Sci 36:1121\u20131126. https:\/\/doi.org\/10.1007\/s10072-015-2207-0","journal-title":"Neurol Sci"},{"key":"6414_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000375304","volume":"24","author":"D Shehab","year":"2015","unstructured":"Shehab D, Al-Jarallah K, Abdella N, Mojiminiyi OA, Al Mohamedy H (2015) Prospective evaluation of the effect of short-term oral vitamin d supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract 24:250\u2013256. https:\/\/doi.org\/10.1159\/000375304","journal-title":"Med Princ Pract"},{"key":"6414_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.dsx.2018.12.014","volume":"13","author":"A Ghadiri-Anari","year":"2019","unstructured":"Ghadiri-Anari A, Mozafari Z, Gholami S, Khodaei SA, Aboutorabi-Zarchi M, Sepehri F, Nadjarzade A, Rahmanian M, Namiranian N (2019) Dose vitamin D supplementations improve peripheral diabetic neuropathy? A before-after clinical trial. Diabetes Metab Syndr 13:890\u2013893","journal-title":"Diabetes Metab Syndr"},{"key":"6414_CR27","doi-asserted-by":"publisher","unstructured":"Grim J, Ticha A, Hyspler R, Valis M, Zadak Z (2017) Selected risk nutritional factors for chemotherapy-induced polyneuropathy. Nutrients 9. https:\/\/doi.org\/10.3390\/nu9060535","DOI":"10.3390\/nu9060535"},{"key":"6414_CR28","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s001250051443","volume":"42","author":"S Riaz","year":"1999","unstructured":"Riaz S, Malcangio M, Miller M, Tomlinson DR (1999) A vitamin D(3) derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia 42:1308\u20131313","journal-title":"Diabetologia"},{"key":"6414_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183491","volume":"12","author":"J Youk","year":"2017","unstructured":"Youk J, Kim YS, Lim JA, Shin DY, Koh Y, Lee ST, Kim I (2017) Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS ONE 12:e0183491. https:\/\/doi.org\/10.1371\/journal.pone.0183491","journal-title":"PLoS ONE"},{"key":"6414_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1523\/JNEUROSCI.21-01-00098.2001","volume":"21","author":"LD Brewer","year":"2001","unstructured":"Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM (2001) Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 21:98\u2013108","journal-title":"J Neurosci"},{"key":"6414_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1043-2760(01)00547-1","volume":"13","author":"E Garcion","year":"2002","unstructured":"Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 13:100\u2013105","journal-title":"Trends Endocrinol Metab"},{"key":"6414_CR32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1023\/B:BIRY.0000040196.65686.2f","volume":"69","author":"AV Kalueff","year":"2004","unstructured":"Kalueff AV, Eremin KO, Tuohimaa P (2004) Mechanisms of neuroprotective action of vitamin D(3). Biochemistry (Mosc) 69:738\u2013741","journal-title":"Biochemistry (Mosc)"},{"key":"6414_CR33","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00520-016-3126-1","volume":"24","author":"J Wang","year":"2016","unstructured":"Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, Ibrahim E, Treisman J, Masri M, Berenson JR (2016) Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and\/or thalidomide and is associated with severe neuropathy. Support Care Cancer 24:3105\u20133110. https:\/\/doi.org\/10.1007\/s00520-016-3126-1","journal-title":"Support Care Cancer"},{"key":"6414_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04942-7","author":"K Nath","year":"2019","unstructured":"Nath K, Ganeshalingam V, Ewart B, Heyer E, Watt K, Birchley A, Casey J, Lai HC, Morris E, Hodges G (2019) A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-019-04942-7","journal-title":"Support Care Cancer"},{"key":"6414_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","volume":"13","author":"M Di Maio","year":"2016","unstructured":"Di Maio M, Basch E, Bryce J, Perrone F (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13:319\u2013325. https:\/\/doi.org\/10.1038\/nrclinonc.2015.222","journal-title":"Nat Rev Clin Oncol"},{"key":"6414_CR36","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","volume":"22","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, Chen WH, Sridhara R, Farrell AT, Keegan P, Kim G, Pazdur R (2016) Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res 22:1553\u20131558. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2035","journal-title":"Clin Cancer Res"},{"key":"6414_CR37","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930. https:\/\/doi.org\/10.1210\/jc.2011-0385","journal-title":"J Clin Endocrinol Metab"},{"key":"6414_CR38","unstructured":"European Medicines Agency (2019) Summary of product characteristics of colecalciferol. https:\/\/www.medicines.org.uk\/emc\/product\/2382\/smpc. Accessed January, 16 2020"},{"key":"6414_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.annepidem.2007.12.001","volume":"19","author":"MF Holick","year":"2009","unstructured":"Holick MF (2009) Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 19:73\u201378. https:\/\/doi.org\/10.1016\/j.annepidem.2007.12.001","journal-title":"Ann Epidemiol"},{"key":"6414_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214446","volume":"14","author":"A Cransac","year":"2019","unstructured":"Cransac A, Aho S, Chretien ML, Giroud M, Caillot D, Boulin M (2019) Adherence to immunomodulatory drugs in patients with multiple myeloma. PLoS ONE 14:e0214446. https:\/\/doi.org\/10.1371\/journal.pone.0214446","journal-title":"PLoS ONE"},{"key":"6414_CR41","unstructured":"NHG-standaard (2018) Laboratoriumdiagnostiek Vitamine D-defici\u00ebntie. https:\/\/www.nhg.org\/themas\/publicaties\/laboratoriumdiagnostiek-vitamine-d--deficientie-volledige-tekst"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06414-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06414-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06414-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T05:07:23Z","timestamp":1677474443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06414-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6414"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06414-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,17]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical Centre Leeuwarden (No. NL58290.09916).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent prior to participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}